SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Neurocrine Biosciences,
Inc. (Nasdaq: NBIX) today announced its financial results for the fourth
quarter and year ended December 31, 2007. For the three months ended
December 31, 2007, the Company reported a net loss of $128.0 million or
$3.35 loss per share compared to a net loss of $14.7 million or $0.39 loss
per share for the same period last year. For the year ended December 31,
2007, the Company had a net loss of $207.3 million, or $5.45 loss per share
compared with a net loss of $107.2 million, or $2.84 loss per share in
2006. The increase in net loss is primarily the result of a one-time
non-cash impairment charge of $94.0 million related to the write-off of the
indiplon prepaid royalty during the fourth quarter of 2007. Additionally,
the Company incurred a $6.9 million charge related to a severance program
enacted in December 2007.

Revenues for the fourth quarter of 2007 were $0.5 million compared with
$9.4 million for the same period last year. The Company recognized $0.5
million in license fee revenues during the fourth quarter of 2007 related
to the licensing of the Japanese rights for indiplon to Dainippon Sumitomo
Pharma Co. Ltd. (DSP). During the fourth quarter of 2006, the Company
recognized license fee revenues arising from the Pfizer, Inc. (Pfizer)
collaboration of $0.7 million. Additionally, the Company recognized
milestones related to CRF drug candidate development under the
GlaxoSmithKline (GSK) agreement of $8.0 million for the fourth quarter of
2006.

Revenues for the year ended December 31, 2007, were $1.2 million,
compared with $39.2 million for 2006. The decrease in revenues for the year
ended December 31, 2007 is primarily due to the cancellation of our
col/p>

Total revenues 532 9,440 1,224 39,234

Operating expenses:

Research and development 24,340 18,608 81,985 97,678

Sales, general and

administrative 10,786 7,095 37,481 54,873

Prepaid Royalty Write-Off 94,000 - 94,000 -

Total operating expenses 129,126 25,703 213,466 152,551

Loss from operations (128,594) (16,263) (212,242) (113,317)

Other income and (expenses):

Interest income and

expense, net 616 1,543 4,814 6,576

Other income and

(expense), net 3 8 129 (464)

Total other income 619 1,551 4,943 6,112

Net loss $(127,975) $(14,712) $(207,299) $(107,205)

Net loss per common share:

Basic and diluted $(3.35) $(0.39) $(5.45) $(2.84)

Shares used in the calculation

of net loss per common share:

Basic and diluted 38,165 37,894 38,009 37,722

NEUROCRINE BIOSCIENCES, INC.

Condensed Consolidated Balance Sheets

(in thousands)

December 31, December 31,

2007 2006

(unaudited)

Cash, cash equivalents and

marketable securities $179,385 $182,604

Other current assets 3,563 11,054

Total current assets 182,948 193,658

Property and equipment, net 82,598 91,378

Prepaid royalty - 94,000

Other non-current assets 11,108 10,641

Total assets $276,654 $389,677

Current liabilities $29,907 $20,116

Long-term liabilities 128,050 54,845

Stockholders' equity 118,697 314,716

Total liabilities and

stockholders' equity $276,654 $389,677

laboration agreement with Pfizer. The Company recognized $6.5 million
and $6.6 million in the form of license fees and sponsored development
funding, respectively under the Pfizer collaboration agreement for the year
ended December 31, 2006. The sales force allowance earned under the
collaboration agreement was $16.5 million for 2006. The Company also
recognized milestones under the GSK collaboration agreement of $9.0 million
during 2006.

Research and development expenses were $24.3 million in the fourth
quarter of 2007 compared to $18.6 million for the fourth quarter of 2006,
primarily resulting from severance costs of $4.9 million and higher
external development costs related to the GnRH clinical program, offset by
lower laboratory and personnel costs. For the year ended December 31, 2007,
research and development expenses were $82.0 million compared to $97.7
million last year. This $15.7 million decrease in year-to-date research and
development expenses is due to lower personnel and laboratory costs, a
result of our staff reductions in 2006 and lower external development
costs.

Sales, general and administrative expenses were $10.8 million for the
fourth quarter 2007 compared with $7.1 million for the same period in 2006,
a direct result of $2.0 million in severance costs incurred in 2007, and
increased marketing activities in the fourth quarter of 2007. For the year
ended December 31, 2007 sales, general and administrative expenditures
totaled $37.5 million compared to $54.9 million in 2006. The decrease in
expenses is primarily a result of our severance program enacted during the
third quarter of 2006.

The Company's balance sheet at December 31, 2007 reflected total assets
of $276.7 million including cash, cash equivalents, and marketable
securities of $179.4 million, compared with balances at December 31, 2006
of $389.7 million and $182.6 million, respectively. The Company's cash
reserves were replenished during the fourth quarter to beginning of year
levels. This was achieved through receipt of the $20.0 million upfront
license fee from DSP for licensing of indiplon in Japan, and the sale and
leaseback of the Company's campus which netted approximately $61.0 million
in cash.

Financial Guidance for 2008

Exclusive of any new partnering agreements, the Company expects to have
a net loss of approximately $75 to $80 million for 2008, and the cash burn
from ongoing operations in 2008 is expected to be approximately $65 to $70
million.

"As we begin 2008 we are focusing the Company's resources towards
advancing our clinical pipeline, led by three Phase II programs. Our GnRH
compound is now in two large Phase II studies and this important program,
with its multiple disease targets, continues to progress in partnering
discussions. Our CRF collaboration with GSK has multiple compounds in
clinical development for both CNS and GI disorders. Additionally, our
Urocortin 2 program is scheduled to complete its preclinical toxicology
studies this year in order to continue its Phase II clinical program in
acute decompensated heart failure. We look forward to moving these programs
and our preclinical targets ahead this year," said Kevin C. Gorman,
President and CEO of Neurocrine Biosciences.

Indiplon update

On December 12, 2007, we received an action letter from the FDA stating
that indiplon 5mg and 10mg capsules are Approvable (Approvable Letter). The
Approvable Letter did not raise any of the issues previously raised by the
FDA in the May 15, 2006 Approvable Letter.
The Approvable Letter spelled out the following new requirements:

-- An additional objective/subjective clinical trial in the elderly.

-- A safety study assessing the rates of adverse events occurring with

indiplon when compared to a marketed product.

-- A preclinical study to evaluate indiplon administration during the

third trimester of pregnancy.

The Company has an end of review meeting to discuss the contents of the
Approvable Letter scheduled with the FDA during the first quarter of 2008.
We will provide an update on the results of that FDA meeting during our
first quarter 2008 earnings call.

Pipeline Highlights

The Company's clinical development group and corporate partners are
advancing its lead programs through development. Neurocrine scientists
continue to build the Company's pipeline and meet the Company-wide goal of
bringing one new compound into development each year.

-- In mid December, we completed enrollment of patients in the 6-month

Phase IIb clinical trial with NBI-56418.

-- A new tablet formulation has been selected based upon optimal

manufacturing processes and tablet characteristics to be used in all

future studies.

-- An additional Phase IIb clinical trial with the new formulation tablet

was initiated in 2007 utilizing clinical endpoints that incorporate

recent guidance from the FDA.

The Company has completed enrollment in a Phase IIb study in which 252
patients with endometriosis will be treated over a 6-month period. This
multi-center, randomized, double-blind, study includes three treatment
groups, with two doses of NBI-56418, 150 mg once a day and 75 mg twice
daily, and an active comparator, Depo-Provera(R). In addition to confirming
the effect of NBI-56418 on endometriosis symptoms, this study is designed
primarily to assess the impact of longer term treatment on bone mineral
density as measured by DXA scan at the conclusion of dosing and at 6-months
and 12-months post-treatment. Topline results from the 6-month treatment
period are expected in mid-2008. The study will continue after the
treatment period for DXA scans and safety assessments. The 6-month results,
together with data from the other Phase II studies, will be the basis for
securing agreement on a registration plan with the FDA.

The Company is also conducting two additional randomized placebo
controlled Phase II clinical trials in 2008. The clinical endpoints for
both of these trials will be a reduction in pelvic pain associated with
endometriosis, utilizing a scale proposed by the FDA. The first Phase II
trial will include our selected commercial formulation tablet in two doses,
(150 mg and 250 mg); this trial was initiated in late 2007 and is expected
to enroll approximately 150 patients. The Company expects topline results
from the first three months of treatment at the end of 2008 or early 2009.
The second trial is a four arm comparator trial of two doses of NBI-56418,
placebo or Leuprolide Depot. This trial will be conducted in
Central/Eastern Europe and will begin enrollment in the first half of 2008.
Topline data from this 3-month double-blind trial should be available in
early 2009.

Neurocrine is also investigating the potential of certain GnRH
antagonists in treating other hormone-dependent diseases in Men's and
Women's Health.

-- GSK has completed enrollment of patients in a second Phase II "proof of

concept" trial with 876008 in irritable bowel syndrome (IBS).

-- Additional lead compounds for depression and anxiety include 561679,

which has completed a Phase I multi-dose trial, and will be moving into

a Phase II depression trial in 2008; and 586529 which has started a

Phase I single escalating dose trial.

The CRF collaboration between Neurocrine and GSK has identified
multiple unique high affinity and selective antagonists for the CRF1
receptor that are currently in clinical development for mood disorders and
IBS. GSK has completed the first Phase II "proof of concept" clinical trial
with a lead CRF1 receptor antagonist compound, 876008, for SocAD and has
completed recruiting for a Phase II "proof of concept" clinical trial in
IBS.

In the first double-blind, randomized, placebo controlled, multiple
dose study to evaluate the safety and efficacy of the CRF1 receptor
antagonist compound in patients with SocAD no statistically significant
differences were observed in the key efficacy endpoints between 876008 and
placebo at 12 weeks. This study included more than 200 adult subjects and
assessed efficacy, safety, tolerability and pharmacokinetics of the
compound and the drug was generally well tolerated with no serious adverse
events reported.

The second "proof of concept" trial is a Phase II double-blind,
randomized, placebo controlled study to evaluate the safety and efficacy of
876008 in patients with IBS. Approximately 130 patients meeting established
diagnostic criteria for IBS have been entered into this cross-over design
trial. Standard assessments of safety, tolerability and pharmacokinetics
will be conducted. The clinical endpoints reflect change in symptom
frequency and severity via validated scales for IBS and the data should be
available in the second half of 2008.

GSK is advancing the second lead CRF1 receptor antagonist, 561679, into
a Phase II depression study later this year. GSK has also initiated a Phase
I single dose escalating clinical trial with 586529, an additional CRF1
receptor antagonist compound.

Additional Programs:

Urocortin 2 for congestive heart failure (CHF):

-- Initiation of longer term (up to 72 hours in duration) Phase II

clinical trials of urocortin 2 are awaiting additional preclinical

data. We have identified a preclinical formulation that allows for the

-- Neurocrine completed a Phase I clinical trial with sNRI for neuropathic

pain. The single ascending dose study in healthy volunteers

demonstrated that the drug was well tolerated and the pharmacokinetic

characteristics were suitable for clinical development. The Company

will not proceed into multi-dose Phase I clinical trials at this time

in order to focus resources on the GnRH program.

Conference Call and Webcast Today at 5:00 PM Eastern Time

Neurocrine will hold a live conference call and webcast today at 5:00
p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the
live conference call by dialing 1-800-862-9098, (US) or 785-424-1051
(International) using the conference ID: 7NBIX2. The call can also be
accessed via the webcast through the Company's website at
http://www.neurocrine.com

If you are unable to attend the Webcast and would like further
information on this announcement please contact the Investor Relations
Department at Neurocrine Biosciences at (858) 617-7600. A replay of the
Conference Call will be available approximately one hour after the
conclusion of the call by dialing 1-800-723-0520 (US) or 402-220-2653
(International) using the conference ID: 7NBIX2. The call will be archived
for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on
neurological and endocrine diseases and disorders. Our product candidates
address some of the largest pharmaceutical markets in the world including
insomnia, anxiety, depression, irritable bowel syndrome, endometriosis and
CNS related disorders. Indiplon was licensed from DOV Pharmaceuticals in
1998. Neurocrine Biosciences, Inc. news releases are available through the
Company's website via the internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. Among the factors that could cause actual results to differ
materially from those indicated in the forward-looking statements are risks
and uncertainties associated with Neurocrine's business and finances in
general, as well as risks and uncertainties associated with the Company's
indiplon program, GnRH program, R & D pipeline and Company overall.
Specifically, the risks and uncertainties the Company faces with respect to
its indiplon program include, but are not limited to; risk that the Company
will not be able to address issues and or requests set forth in the
December 12, 2007 indiplon capsule action letter from the FDA in a timely
manner if at all; risk that the Company will not be able to address issues
and or requests set forth in the December 12, 2007 indiplon capsule action
letter from the FDA in a manner acceptable to the FDA if at all; the risk
that FDA may reject any future indiplon regulatory filings or find them
incomplete or insufficient; and risk that indiplon approval and subsequent
commercialization may be significantly or indefinitely delayed or never
accomplished. The Company also faces risks and uncertainties with respect
to the Company's GnRH program including risk that the Company's GnRH
clinical trials will fail to demonstrate that the Company's clinical
candidates are safe and effective; risk that the Company's GnRH clinical
candidates will not proceed to later stage clinical trials; risks
associated with the Company's dependence on corporate collaborators for
development, commercial manufacturing and marketing and sales activities.
In addition, the Company faces risks and uncertainties with respect to the
Company's R & D pipeline including risk that the Company' research stage
GnRH receptor antagonists, urocortin 2, CRF1 receptor antagonist, and sNRI
clinical candidates will not proceed to later stage clinical trials, risk
that the Company's research programs will not identify pre-clinical
candidates for further development. With respect to its pipeline overall,
the Company faces risk that it will be unable to raise additional funding
required to complete development of all of its product candidates; risk
relating to the Company's dependence on contract manufacturers for clinical
drug supply; risks associated with the Company's dependence on corporate
collaborators for commercial manufacturing and marketing and sales
activities; uncertainties relating to patent protection and intellectual
property rights of third parties; risks and uncertainties relating to
competitive products and technological changes that may limit demand for
the Company's products; and the other risks described in the Company's
report on Form 10-K for the year ended December 31, 2006 and Form 10-Q for
the quarter ended September 30, 2007. Neurocrine undertakes no obligation
to update the statements contained in this press release after the date
hereof.

(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...

(Date:9/12/2017)... 12, 2017 EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...

(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...

(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...

(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...

(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...

(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...